We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

"Off-the-Shelf" Cancer Vaccine Delivers Double Punch to Tumors


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of ""Off-the-Shelf" Cancer Vaccine Delivers Double Punch to Tumors"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

When normal cells experience DNA damage, they present proteins on their outer surfaces that serve as a “kill me” signal to both T cells and natural killer (NK) cells, members of the immune system that come and destroy the labeled cells. Some cancer cells, however, have figured out how to clip those proteins off of their surfaces, allowing them to evade detection by the immune system’s search-and-destroy team.


A team of scientists from the Wyss Institute and Dana-Farber Cancer Institute (DFCI) led by Kai Wucherpfennig, M.D., Ph.D. has developed a novel cancer vaccine that targets this process by inducing the body to manufacture antibodies against the “kill me” proteins. This approach effectively locks them in place on cancer cells’ surfaces, preventing the cells from destroying them. That, in turn, makes them available to trigger killing responses from both T and NK cells.


The research was published in Nature on May 25 2022, and is described in an article in STAT News published on the same day.


The team demonstrated the vaccine’s usefulness in mice with melanoma and triple-negative breast cancer, both of which frequently metastasize even after a patient has surgery to remove existing tumors. They surgically removed the animals’ tumors, then administered the vaccine, and saw that the rate of metastasis was greatly reduced. When they re-challenged some of the vaccinated animals with cancerous tumors four months later, none of them developed the disease.


The vast majority of other cancer vaccines must be personalized for each individual patient because they are designed to target specific molecules on the surface of a patient’s tumor. This vaccine, in contrast, can be used “off-the-shelf” without the need for a lengthy and expensive personalization process, because the “kill me” protein is present in most cell types. Also, because it recruits both T cells and NK cells, it can potentially treat cancers that are resistant to other types of cancer vaccines.


“This approach has great potential to treat patients suffering from a number of types of cancer, and really demonstrates the power of combining fundamental immunology insight with new technologies developed at the Wyss,” said co-author Dave Mooney, Ph.D., who is a Core Faculty member of the Wyss Institute and the Robert P. Pinkas Family Professor of Bioengineering at Harvard’s John A. Paulson School of Engineering and Applied Sciences (SEAS).


Additional authors of the paper include co-first authors Soumya Badrinath from DFCI and Harvard Medical School (HMS), Maxence Dellacherie and Aileen Li from the Wyss Institute and SEAS, and Shiwei Zheng from DFCI; Xixi Zhang and Sabrina Haag from DFCI and HMS; Miguel Sobral from the Wyss Institute and SEAS; Jason Pyrdol, Kathryn Smith, Yuheng Lu, and Guo-Cheng Yuan from DFCI; Hamza Ijaz from the Wyss Institute; Fawn Connor-Stroud from Emory University; Tsuneyasu Kaisho from Wakayama Medical University; and Glenn Dranoff from the Novartis Institutes for BioMedical Research.


Reference: Badrinath S, Dellacherie MO, Li A, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022:1-7. doi: 10.1038/s41586-022-04772-4


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement